BofA Securities Double Downgrades Acumen Pharmaceuticals, Inc. (ABOS) to Underperform

November 2, 2026 4:59 AM EST Send to a Friend
BofA Securities analyst Geoff Meacham downgraded Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) from Buy to Underperform with a price target of ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login